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Abstract
Background—Psychotic symptoms represent one of the most severe and functionally impairing 
components of several psychological disorders. One group with particularly high rates of 
psychotic symptoms is chronic substance users. However, the literature on psychotic symptoms 
and substance use is quite narrow and has focused almost exclusively on drug-induced psychosis, 
neglecting the population of substance users with psychotic symptoms occurring independently of 
acute drug effects.
Method—The current study examined demographics, substance dependence, and psychiatric 
comorbidities among substance users with current (CurrSx), past (PastSx), and no psychotic 
symptoms (NoSx). Patients (n = 685) were sequential admissions to a residential substance use 
treatment center from 2006 to 2009.
Results—Compared to NoSx, those who endorsed CurrSx were significantly more likely to meet 
criteria for lifetime alcohol dependence and lifetime amphetamine dependence. CurrSx were more 
likely than PastSx to meet for lifetime cannabis dependence. Additionally, CurrSx were more 
likely to meet criteria for a comorbid psychiatric disorder compared to NoSx, and evidenced a 
greater number of current psychiatric disorders. NoSx were less likely than both CurrSx and 
PastSx to meet criteria for Borderline Personality Disorder.
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Conclusion—Individuals with non-substance induced psychotic symptoms appear to meet 
criteria for specific substance use disorders and psychiatric disorders at higher rates than those 
without psychotic symptoms; these effects were most evident for those with current as opposed to 
past symptoms. Findings suggest that these individuals may need specialized care to address 
potential psychiatric comorbidities and overall greater severity levels relative to substance users 
without psychotic symptoms.
Keywords
Substance dependence; Psychiatric disorders; Psychotic symptoms; Comorbidity inpatient 
treatment
1. Introduction
Psychotic symptoms, including delusional beliefs and hallucinatory experiences, are 
associated with significant psychosocial impairment (Granholm et al., 2009, 2011; Tarrier et 
al., 1993) and may place affected individuals at a heightened risk of developing clinically 
relevant psychotic disorders including schizophrenia (Fonseca-Pedrero et al., 2011; Laurens 
et al., 2007; Lataster et al., 2009). Incidence of psychotic symptoms in the general 
population has been reported to range from 4.8% to 8.3% depending on the specific 
symptom examined (Nuevo et al., 2012). Substance users represent one group with 
particularly high rates of psychotic symptoms (Kuzenko et al., 2011; Smith et al., 2009), and 
these symptoms can pose significant challenges during substance use treatment. Indeed, 
individuals with substance use disorders and co-occurring psychosis frequently evidence 
less motivation to change, reduced treatment engagement, and an increased likelihood of 
dropping out of treatment prematurely relative to individuals with substance use disorders 
alone (for review, see Horsfall et al., 2009).
Despite the clear negative impact that psychotic symptoms can have on substance users, 
relatively little is known about this group, as the available literature on substance use and 
psychotic symptoms has focused almost exclusively on acute drug-induced psychosis 
(Barnett et al., 2008; Smith et al., 2009). In the few studies that have examined non-
substance induced psychosis among substance users, the studies were often limited to a 
narrow set of drug classes (e.g., Dekker et al., 2009; Kuzenko et al., 2011; Salo et al., 2011; 
Lichlyter et al., 2011) and most did not address key variables such as psychiatric 
comorbidity. One study that did assess a wide range of drug classes and psychiatric 
comorbidities reported elevated rates of dependence and comorbidity among individuals 
endorsing psychotic symptoms (McMillan et al., 2009). However, the methodology utilized 
in this study did not examine specific psychotic symptoms and relied on participant recall of 
previous psychiatric diagnoses made by health care providers. A more recent study 
examining the effects of substance abuse on subsequent psychotic symptoms revealed that a 
significant portion of the occurrence of subclinical psychotic symptoms in adulthood may be 
attributed to excessive cannabis and multiple-drug use during adolescence (Rosller et al., 
2012). However, the design of the study restricts direct causal interpretations and Diagnostic 
and Statistical Manual of Mental Disorders criteria were not used to classify substance use 
in all cases. Additionally, both of these studies (Rosller et al., 2012 and McMillan et al., 
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2009) used a general population rather than participants within a clinical setting for 
substance use treatment. Thus, the field lacks a clear clinical picture of individuals with co-
occurring substance use disorders and non-substance induced psychosis presenting for 
treatment.
To better characterize this particularly at-risk group, the current study examined 
demographic characteristics, substance dependence, and psychiatric comorbidity among 
substance users with current, past, and no psychotic symptoms utilizing the Structured 
Clinical Interview for the DSM-IV and the Diagnostic Interview for Personality Disorders. 
The study was conducted in a residential drug treatment setting that required full detox prior 
to entry and constant sobriety throughout treatment, which holds several strengths for the 
purposes of this report. First, assessing individuals in the context of sobriety allows for the 
isolation of psychotic symptoms from acute drug effects. Second, this approach provides a 
control for contextual factors that may differ between those with and without psychotic 
symptoms outside of the treatment setting that might differentially impact assessment. Third, 
although the residential setting does limit generalizability to the larger group of substance 
users not in treatment or in a less restrictive form of treatment, there are aspects of this 
setting that may increase generalizability by limiting differential self-exclusion by more 
impaired individuals due to the burden of study participation. Specifically, the center takes 
in a broad range of voluntary and court-mandated individuals and once enrolled in the 
center, research participation requires no travel and little other investment on the part of the 
individual. This removal of several barriers to participation and the subsequent impact on 
differential self-selection may be especially important in a study focused on psychotic 
symptoms. The purpose of the current study was to assess results presented in previous 
research indicating that individuals endorsing psychotic symptoms evince a greater 
likelihood of meeting dependence criteria for several substances including marijuana 
(Rosller et al., 2012; Dekker et al., 2009), cocaine (Kuzenko et al., 2011), amphetamines 
(Lichlyter et al., 2011), as well as Poly-drug use (Rosller et al., 2012), within the context of 
the improvements in methodology listed previously. Additionally, we aimed to assess 
previous results indicating that individuals endorsing psychotic symptoms often meet 
criteria for mood and anxiety disorders at an increased rate relative to individuals with no 
history of psychotic symptoms (Michail and Birchwood, 2009; Koreen et al., 1993). Lastly, 
we examined differences between individuals endorsing past versus current psychotic 
symptoms in terms of meeting criteria for substance use, mood, and anxiety disorders.
2. Methods
2.1. Participants
Patients (n = 685) were sequential admissions into an inpatient substance use treatment 
facility in Washington, D.C. from 2006 to 2009. The mean age of the sample was 43 (SD = 
10.5). The majority of the sample was male (65.9%) and court-mandated to treatment 
(70.8%). The majority of the sample consisted of African Americans (90.3%), followed by 
Caucasians (4.5%), Hispanics (1.8%), American Indian/Alaskan Natives (.5%), Asians (.
3%), and individuals identifying as “other” (2.6%). At the time of admission into the 
treatment center, participants were required to submit a negative urine drug screen. Those 
Lechner et al. Page 3













with positive drug screens had to complete a detoxification program and evidence no acute 
pharmacological effects of drug use before they were admitted to the facility; there was 
great variety in the detoxification programs used across participants but most included 
medical assistance over several days. Inpatient treatment typically ranged from 28 to 180 
days and was dependent on the patients’ treatment funding sources. Patients were only 
permitted to leave the facility for scheduled appointments such as psychiatric and primary 
care appointments. Drug-testing occurred on a weekly basis and any use was grounds for 
immediate removal from the center. Because patients were assessed early in their treatment, 
none had been removed from treatment at the time of assessment. Patients were involved in 
a number of daily programs intended to help them develop a substance-free lifestyle. These 
programs were based on Alcoholics Anonymous and Narcotics Anonymous techniques and 
included relapse prevention skills training.
2.2. Recruitment and consent
Intake assessments were conducted by doctoral level graduate students and senior research 
staff with patients during their first week at the inpatient substance use treatment center. The 
assessments served two purposes: (1) to provide diagnostic information to treatment staff at 
the center, and (2) to gather data for the current study. Patients were invited to participate in 
research following the intake assessment and were provided details regarding how 
information collected during the assessment would be used. Data for the current study 
includes only cases where informed consent was obtained from patients following the 
assessment (<5% of patients declined to provide informed consent). The study protocol was 
reviewed and approved by the University of Maryland Institutional Review Board.
2.3. Measurements
Information regarding Axis I disorders and Antisocial Personality Disorder (ASPD) was 
garnered using the Structured Clinical Interview for the Diagnostic and Statistical Manual of 
Mental Disorders IV (SCID-IV; First et al., 1995). A brief assessment of demographic 
information was also included and the Diagnostic Interview for Personality Disorders 
(DIPD) was used to assess Borderline Personality Disorder (BPD), as it has been argued to 
be a more comprehensive measure of BPD than the SCID-IV (Zanarini et al., 1987). Patients 
met criteria for psychotic symptoms using the SCID-IV if they evidenced either delusions or 
hallucinations as defined by the Diagnostic and Statistical Manual of Mental Disorders IV 
(DSM-IV). Current psychotic symptoms were indicated if the individual reported 
experiencing the symptoms in the past month, whereas lifetime psychotic symptoms were 
indicated if psychotic symptoms were reported as ever occurring, but not in the past month. 
In the context of the assessment, we were careful to exclude substance-induced psychotic 
symptoms. In all cases where a psychotic symptom was endorsed, the interviewer only 
indicated the symptom was present if at least one episode was entirely unrelated to acute 
pharmacological effects. This was determined with a very comprehensive timeline of 
substance use and psychiatric symptoms with the requirement that symptoms occur during 
periods of sobriety of at least 3 days. For patients without any period of sobriety the 
assessment focused on ensuring the symptoms occurred outside of periods of acute 
intoxication. As such we feel confident that psychotic symptoms could be separated from 
acute drug effects, but it should be noted that the etiological basis of psychotic symptoms 
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cannot be determined with complete accuracy due to lack of information related to the age 
of onset of the symptoms. Moreover, our assessment could not separate chronic substance 
use effects given the possibility of residual symptoms of substance induced psychotic 
symptoms remaining even after the acute effects of the substance had dissipated.
Patients were diagnosed with current substance dependence with the SCID-IV if they 
endorsed at least three symptoms of dependence for at least one month within the past year 
(all symptoms did not have to meet threshold in the same month). Lifetime dependence was 
diagnosed when patients met threshold at any point in their lives including current 
dependence. Substance abuse was not assessed given the severity of the sample and the 
secondary status of abuse compared to a dependence diagnosis. Interviewers attended to the 
timeline of substance dependence to differentially diagnose Axis I disorders due to 
substance use or other underlying causes. Diagnoses were made only when symptoms could 
not be tied directly to acute substance intoxication or the effects of withdrawal from a 
substance
Extensive training and comprehensive weekly supervision by a doctoral level clinical 
psychologist was provided to interviewers to ensure accuracy of diagnoses. As part of 
training, interviewers viewed the complete video protocol from the developers of the SCID-
IV, conducted two mock interviews using the SCID-IV and the DIPD, observed two full 
interviews by experienced interviewers at the inpatient treatment center, conducted a final 
certification practice interview using the SCID-IV and DIPD, and participated in weekly 
supervision. Clinical questions were addressed and group feedback regarding diagnoses was 
provided during weekly supervision meetings. When disagreements occurred, discussion 
continued until consensus was reached and changes were made.
2.4. Analytic strategy
The completed questionnaires and diagnostic interviews were carefully reviewed and 
checked for completeness or obvious errors before data entry. Data were double entered into 
SPSS (versions 14–18 over the course of the study) so potential inconsistencies or 
inaccuracies could be easily detected and resolved. There were occasional missing data 
points due to non-responses such as: “don’t know” or “refused”. We did not implement any 
imputation procedure for these missing data except for income, where we filled (n = 30 
missing) with the mean income in order to maximize the number of cases included in the 
analyses. Therefore, for the majority of variables examined, the N’s will vary across 
analyses. The current data differs from our previous and independent data collection from 
Chen et al., 2011 where we utilized longer assessments to establish current and past 
dependence independently. Our new strategy was implemented to reduce the duration of the 
SCID as requested by the treatment center. Descriptive analyses, ANOVAs, and chi-square 
tests from the 2 × 3 contingency table were used to examine demographic characteristics and 
the prevalence of substance dependence and psychiatric comorbidities of different 
subgroups by psychotic symptom status. Odds ratios from logistic regressions were utilized 
to report differences between specific subgroups for categorical variables, and Tukey’s HSD 
was used to test the significance of differences in pair-wise comparisons in ANOVA for 
continuous variables. Appropriate demographic covariates were determined by a significant 
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univariate relationship between the demographic variable and the outcome variable for 
logistic regressions. Significant demographic differences were then entered as covariates 
along with the three main psychotic groups; current psychotic symptoms, past psychotic 
symptoms, and no psychotic symptoms. For logistic regressions comparing current 
psychotic symptoms and past psychotic symptoms to no psychotic symptoms, the no 
symptoms group served as the reference point. For logistic regressions comparing current 
psychotic symptoms with past psychotic symptoms, the past psychotic symptoms group 
served as the reference.
3. Results
3.1. Psychotic symptoms and demographic differences
Overall, 10.9% (n = 75) of the sample reported one or more current psychotic symptoms 
(i.e., CurrSx), 6.7% (n = 46) of the sample had past but not current symptoms (PastSx), and 
82.3% (n = 564) of the sample endorsed no psychotic symptoms (NoSx). The rates of 
specific delusions endorsed within the current study ranged from .3% (Bizarre Delusions) to 
5.7% (Delusions of Reference), and rates of specific hallucinations ranged from 2.2% (other 
hallucinations; e.g. Tactile, Olfactory) to 16.8% (auditory hallucinations). Descriptive 
analyses of demographic characteristics by psychotic symptoms status are shown in Table 1; 
only significant differences are discussed here. CurrSx were older (M = 46.1) than PastSx 
(M = 42.2) and NoSx (M = 42.8). CurrSx evidenced a lower percentage of males than NoSx. 
PastSx had a greater rate of unemployment than NoSx. CurrSx, compared to NoSx, had 
higher rates of previous treatment for a substance use disorder, psychiatric treatment, and 
psychiatric medication. No significant group differences were evidenced for race, income 
per month, education, or time in jail.
3.2. Comorbid psychotic symptoms and substance use disorders
Table 2 presents the prevalence of DSM-IV substance use disorders as a function of 
psychotic symptom status. Overall, compared to NoSx, those who endorsed CurrSx evinced 
significantly greater odds of meeting criteria for lifetime alcohol dependence (OR = 1.89, 
C.I. = 1.54–3.10) and lifetime amphetamine dependence (OR = 4.31, C.I. = 1.36–13.55). 
CurrSx demonstrated greater odds of meeting criteria for lifetime cannabis dependence than 
Past Sx (OR = 2.89, C.I. = 1.07–7.79), however no significant differences in lifetime 
cannabis dependence emerged between these groups and NoSx. CurrSx had a higher number 
of lifetime dependence diagnoses (M = 1.88) compared to NoSx (M = 1.42).
3.3. Comorbid psychotic symptoms and other psychiatric disorders
Table 3 indicates the presence of DSM-IV mood, anxiety, and personality disorders as a 
function of psychotic symptom status. Generally, CurrSx had greater odds of meeting 
criteria for a current comorbid psychiatric disorder compared to NoSx (OR = 5.81, C.I. 
2.45–13.74) and PastSx (OR = 3.40 C.I. = .10–.89). CurrSx also evidenced a greater number 
of current psychiatric disorders as compared to NoSx (1.25 vs. .49) and PastSx (1.25 vs. .
58).
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Specific to individual disorders, CurrSx had greater odds of meeting criteria for current 
mood disorders compared to NoSx (OR = 3.36, C.I. = 2.02–5.56) and PastSx (OR = 2.81, 
C.I. = 1.25–6.31). More specifically, CurrSx had greater odds of meeting criteria for Current 
Major Depressive Disorder and Bipolar Disorder compared to NoSx, (See Table 3 for Odds 
Ratios). PastSx also had greater odds of meeting criteria for Current Bipolar Disorder 
compared to NoSx. An examination of current anxiety disorder diagnoses revealed a similar 
pattern to what was observed in current mood disorders. Specifically, CurrSx evidenced 
greater odds for meeting criteria for current anxiety disorders than NoSx (OR = 3.33, C.I. = 
1.91 = 5.78). More specifically, CurrSx demonstrated greater odds for meeting criteria for 
Current Panic Disorder, Current Social Phobia, Current Specific Phobia, Current Obsessive 
Compulsive Disorder, and Current Post-Traumatic Stress Disorder as compared to NoSx 
(See Table 3 for odds ratios). When examining the DSM-IV personality disorders of 
Borderline and Antisocial as a function of psychotic symptom status, CurrSx and PastSx had 
greater odds of meeting criteria for Borderline Personality Disorder than NoSx, (OR = 4.87, 
C.I. = 2.73–8.62) and (OR = 2.53, C.I. = 1.18–5.42), respectively.
4. Discussion
The current study examined rates of substance use disorders and psychiatric disorders 
among those endorsing current, past, or no psychotic symptoms in a sample of substance 
users in residential drug treatment. This paper marks the first effort to our knowledge to 
characterize substance using individuals with psychotic symptoms independent of acute 
substance-induced psychotic symptoms in a clinical setting, with a particular focus on 
demographic characteristics, substance dependence, and psychiatric comorbidities. 
Individuals with comorbid substance dependence and non-drug induced psychotic symptoms 
represent an important population to study as their psychotic symptoms are likely to persist 
following drug cessation, making them a functionally different group than individuals who 
only evidence acute drug-induced psychosis. These functional differences suggest that they 
may have unique treatment needs. As such, knowing more about the prevalence of comorbid 
substance dependencies and psychiatric disorders within this group of individuals is the first 
step toward improving the treatments available to substance users presenting with a dual 
diagnosis.
Regarding substance use disorders, CurrSx differed from NoSx, as the former evidenced 
elevated rates of lifetime alcohol dependence and lifetime amphetamine dependence. It is 
important to note that significant differences in the prevalence of cocaine dependence as a 
function of psychotic symptom status were observed; however when age was entered into 
the logistic regression as a covariate the odds ratios for these variables were not significant. 
Overall, our findings suggest an increased prevalence of lifetime alcohol and amphetamine 
dependence, as well as a greater total number of lifetime substance use disorders, among 
substance-using patients reporting current psychotic symptoms.
The increased prevalence of amphetamine dependence (as well as cocaine dependence 
before controlling for age) among CurrSx is comparable to the findings reported by 
Kuzenko et al. (2011), who reported elevated rates of cocaine use among individuals with a 
history of two or more psychotic symptoms in a community sample. Neither our study, nor 
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Kuzenko et al. examined specific mechanisms driving the apparent relationship between 
psychotic symptoms and the use of cocaine and other stimulants in particular, as opposed to 
other addictive substances. However, some have suggested that brain dopaminergic 
pathways, which are implicated both in drug reward, as well as the neuropathology of 
schizophrenia and psychotic symptoms (i.e., hallucinations and delusions), may play a role 
(Rosller et al., 2012; Chambers et al., 2001; Curran et al., 2004). Given that stimulants, 
including amphetamine and cocaine, exert their addictive properties by working directly on 
dopaminergic receptors, it is perhaps unsurprising that the link between stimulant use and 
psychosis has been reported consistently across studies (Dalmau et al., 1999; Degenhardt 
and Hall, 2001; Farrell et al., 2002; McKetin et al., 2006; Ringen et al., 2008; Salo et al., 
2011). Despite these theoretical connections, more work is certainly needed in order to 
clarify the role of dopaminergic functioning in the relationship between psychosis and 
increased vulnerability to stimulant dependence in particular, as well as the causal 
directionality of these relationships.
Our findings of increased total number of substance dependence diagnoses among 
individuals with CurrSx are also largely consistent with previous findings from research 
conducted in the general population, such that individuals reporting a history of psychotic 
symptoms were more likely to meet criteria for substance dependence across every drug 
examined (McMillan et al., 2009). Our results extend the findings of McMillan et al. (2009) 
as the design of the current study targeted substance users in a clinical setting who are at a 
greater for psychosis relative to the general population, provided greater control for sobriety 
during assessment, and utilized a carefully tailored methodology for assessing psychotic 
symptoms independent of the acute effects of a substance.
Conversely, some of our findings appear to contrast with extant data on psychosis and 
substance use. First, we did not observe increased rates of hallucinogen dependence among 
CurrSx, which contrasts with the significant relationship between psychedelic drug use and 
psychotic symptoms reported in previous studies (Kuzenko et al., 2011). However, it is 
worth noting that Kuzenko et al. (2011) operationalized “substance use” as having used a 
particular drug five times or more in one’s lifetime, whereas the current study assessed 
DSM-IV diagnoses of substance dependence based on responses to a structured interview. 
Similarly, we did not observe the increased prevalence of cannabis use among individuals 
with psychotic symptoms, as is commonly reported in the literature (Rosller et al., 2012; 
Dekker et al., 2009). Again, this apparent inconsistency may in fact be due to our rather 
strict threshold for identifying individuals who use cannabis. That is, we operationalized 
substance use in the current study as meeting DSM-IV criteria for substance dependence. 
Thus, it is possible that individuals with psychotic symptoms may indeed be at an increased 
risk of having used both hallucinogens and cannabis, but they may not necessarily be at an 
increased risk of becoming dependent on these drugs.
Beyond substance use, patients endorsing current psychotic symptoms also had a higher 
prevalence of comorbid psychiatric disorders than those without psychotic symptoms. 
Patients endorsing current psychotic symptoms were more likely than those with no history 
of psychotic symptoms to have comorbid mood and anxiety disorders, an expected result 
given that mood and anxiety disorders have been associated with both psychosis (Michail 
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and Birchwood, 2009; Koreen et al., 1993) and withdrawal from chronic drug use (e.g., 
Koob, 2010). Additionally, individuals with current or past psychotic symptoms were more 
likely than individuals with no history of psychotic symptoms to meet diagnostic criteria for 
Borderline Personality Disorder. Given the severity of this disorder, as well as the 
overlapping diagnostic criteria with psychosis (e.g., stress-induced paranoia in BPD), the 
differences could be expected. The absence of a significant difference in BPD rates between 
CurrSx and PastSx also is somewhat expected given the largely stable nature of this 
personality disorder over the lifetime (Miller et al., 1993; Trull et al., 2000).
Overall, findings suggest that substance users with co-occurring psychotic symptoms in 
residential drug treatment evidence a higher prevalence of dependence on alcohol and 
amphetamine, and a higher prevalence of psychiatric disorders. However, this study 
included limitations that are important to consider when interpreting the results. First, the 
sample consisted of individuals entering an inpatient treatment center for substance use 
rehabilitation, a group that is important for study but certainly not generalizable to all 
substance users. Second, the sample was also limited to largely one race and a specific 
geographic location, Washington, DC, which may have affected the types of substances used 
most frequently, and the demographics of the patient population. Therefore, this study 
should be supplemented with replication among additional populations and in other settings. 
Although biological testing is conducted and a negative urine drug screen is required before 
admission to the treatment facility, it is possible that patients could be experiencing 
prolonged withdrawal effects, which could be responsible for some of the psychotic 
symptoms endorsed. Additionally, recall bias may have influenced reporting of lifetime 
psychotic symptoms. The current study was also limited by the small sample size of 
individuals endorsing sedative, current amphetamine, and poly-drug dependence. Future 
studies should include adequate samples of these individuals to draw conclusions regarding 
the relations between these particular substance use disorders and psychotic symptom status. 
Additionally, the use of substance dependence as a criterion for inclusion in the current 
analysis rather than substance use limits the generalizability of the findings beyond 
individuals meeting full criteria for dependence and neglects individuals who are using at 
less severe levels. Similarly, individuals were included in the CurrSx and PastSx group 
categories if they reported any number of unusual perceptual experiences (e.g., visual, 
auditory, olfactory, or tactile hallucinations) or unusual beliefs that were inconsistent with 
their cultural background (e.g., persecutory, grandiose, or other unusual delusions); 
however, participants in the current study were not diagnosed with any particular DSM-IV 
psychotic disorder, such as schizophrenia. Therefore, it is unclear if our findings will 
necessarily generalize to populations of individuals diagnosed with schizophrenia. Finally, 
lack of information on age of onsets for psychotic symptoms, psychiatric disorders, and 
substance use disorders made it impossible to judge the potential causal relationships 
between psychotic symptoms and substance use disorders, or between psychotic symptoms 
and other psychiatric disorders. Future studies may seek to use longitudinal designs to 
elucidate the temporal relationships between the onset of each disorder type, and identify the 
directionality of any causal relationships that exist.
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Limitations aside, the current study represents an important first step in understanding the 
clinical characteristics of substance users with non-substance induced psychotic symptoms. 
Results indicated that individuals with psychotic symptoms largely met criteria for specific 
substance use disorders and psychiatric disorders at higher rates than those not experiencing 
psychotic symptoms. These effects tend to be more pronounced among those with current 
psychotic symptoms relative to past psychotic symptoms but were evident for some 
psychiatric conditions regardless of whether the psychotic symptoms were current or past, 
and these relationships hold even after controlling for relevant demographic characteristics. 
Future research will need to replicate this work in other settings with more diverse samples, 
while working to identify potential mechanisms underlying the relationship between 
psychotic symptoms and psychiatric comorbidity among substance users, as well as the 
directionality of any causal relationships. Moreover, future researchers should work to 
identify more effective strategies to improve assessment and intervention for these highly 
vulnerable individuals.
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